Latest Innovation News

Jatcorp Limited reported a strong 36% revenue increase to $23 million for the half-year ended December 2025, narrowing its net loss and expanding its footprint across Asia Pacific markets despite ongoing legal challenges in China.

BrainChip Holdings Ltd reported a striking 374% jump in revenue for 2025, yet the company still posted a substantial operating loss of over US$20 million. The results reveal mixed signals for investors watching the semiconductor innovator’s path forward.

Zimplats Holdings Limited reported a remarkable half-year performance with revenue up 83% and profit before tax surging over 2,100%, driven by higher metal prices and operational gains. Capital projects and sustainability efforts remain on track amid a challenging Zimbabwean environment.

Beonic Limited reported a 5.5% revenue increase to $11.2 million and reduced its net loss to $1.44 million for the half-year ending December 2025. The company also repaid a $4.65 million loan and secured a major $7.3 million contract to deploy passenger flow management solutions across seven Moroccan airports.

PointsBet Holdings Limited reports a 4% revenue increase in H1 FY26 following MIXI’s acquisition of a controlling stake, with contrasting performances in Australia and Canada shaping the group’s outlook.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

Pilot Energy is advancing Australia’s first Direct Air Capture demonstration facility at its Cliff Head site, aiming to start operations by mid-2026 and pave the way for a large-scale carbon removal plant.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Lynas Rare Earths Ltd has reported a striking half-year turnaround with a 1260% surge in net profit, underpinned by rising rare earth prices and strategic expansions. The company also completed a major equity raise to fuel its ambitious Towards 2030 growth plan.